background
despit
high
burden
respiratori
infect
import
earli
accur
diagnosi
simpl
diagnost
test
rule
viral
infect
caus
respiratori
symptom
method
perform
rna
sequenc
human
nasal
epitheli
cell
follow
stimul
intracellular
viral
recognit
receptor
rigi
next
evalu
whether
measur
identifi
host
mrna
protein
patient
nasopharyng
swab
could
predict
presenc
respiratori
viru
sampl
result
first
studi
show
signatur
mrna
oasl
predict
respiratori
viru
detect
accuraci
confid
interv
ci
identifi
protein
correl
viru
detect
second
studi
elev
protein
level
identifi
sampl
contain
respiratori
virus
includ
virus
initi
test
panel
overal
area
curv
auc
valu
auc
ci
auc
ci
conclus
host
antivir
mrna
singl
host
protein
detect
use
nasopharyng
swab
accur
predict
presenc
viral
infect
approach
hold
promis
develop
rapid
costeffect
test
improv
manag
patient
respiratori
ill
acut
respiratori
ill
extrem
common
account
million
outpati
ill
million
hospit
per
year
usa
alon
viral
infect
common
caus
ill
usual
diagnosi
exclus
current
test
rule
viral
infect
often
prohibit
cost
time
simpl
panvir
test
rule
viral
caus
respiratori
symptom
could
tremend
posit
impact
facilit
rapid
diagnosi
improv
patient
care
enabl
effici
use
medic
resourc
million
patient
respiratori
ill
current
diagnost
strategi
rule
viral
infect
requir
test
number
distinct
virus
caus
similar
symptom
test
identifi
featur
specif
viru
common
test
use
polymeras
chain
reaction
pcr
base
identif
viral
genom
viral
antigen
detect
test
panel
suspect
virus
time
consum
andor
expens
fals
neg
patient
infect
viru
panel
identifi
one
mani
clinic
similar
virus
caus
respiratori
ill
usual
impact
treatment
virusspecif
therapi
avail
influenza
one
promis
approach
develop
panvir
test
focu
biomark
indic
bodi
respond
viral
infect
sever
recent
studi
demonstr
gene
express
pattern
blood
cell
plasma
indic
presenc
viral
infect
recent
brief
report
show
level
certain
host
mrna
detect
respiratori
swab
correl
symptomat
viral
infect
find
demonstr
promis
use
host
respons
develop
panvir
diagnost
test
therefor
perform
studi
evalu
whether
biomark
antivir
respons
could
identifi
virusposit
nasopharyng
swab
use
swab
sent
health
care
system
respiratori
viru
test
sought
identifi
host
protein
well
mrna
could
indic
viral
infect
sampl
type
immunoassaybas
test
common
use
laboratori
pointofcar
test
guid
vitro
rna
sequenc
rnaseq
experi
nasal
epitheli
cell
first
studi
prospect
examin
perform
signatur
host
mrna
predict
viral
infect
also
use
sampl
retrospect
identifi
promis
potenti
protein
biomark
detect
swabassoci
viral
transport
medium
second
studi
prospect
evalu
protein
found
high
correl
level
protein
presenc
viral
infect
report
find
indic
great
potenti
develop
simpl
panvir
diagnost
test
identifi
patient
respiratori
viru
infect
primari
human
nasal
epitheli
cell
obtain
commerci
promocel
grown
begm
medium
lonza
hydrocortison
epinephrin
supplement
remov
prior
stimul
cell
transfect
rigi
ligand
also
known
gener
gift
pyle
lab
use
lipofectamin
invitrogen
incub
hour
raw
read
rnaseq
experi
trim
sequenc
adaptor
lowqual
region
btrim
trim
read
map
human
genom
count
read
gene
base
ensembl
annot
releas
differenti
express
analysi
done
calcul
adjust
p
valu
rnaseq
data
deposit
ncbi
gene
express
omnibu
geo
access
number
gse
studi
use
sampl
sent
yalenew
hospit
ynhh
diagnost
virolog
laboratori
patient
health
care
provid
sampl
collect
window
select
high
test
volum
winter
month
multipl
virus
circul
base
avail
personnel
process
sampl
research
studi
sampl
includ
direct
fluoresc
antigen
dfa
test
order
respiratori
pcr
panel
order
studi
requir
dfaneg
sampl
sampl
adequ
qualiti
perform
dfa
test
determin
microscopi
studi
includ
nasopharyng
np
swab
collect
viral
transport
medium
day
sampl
store
maximum
hour
prior
centrifug
separ
storag
cell
pellet
lysi
buffer
supernat
studi
includ
viral
transport
medium
np
swab
sent
ynhh
lab
week
decemb
store
sampl
deidentifi
code
clinic
laboratori
protocol
approv
yale
human
investig
committe
investig
respons
reversetranscript
quantit
pcr
rtqpcr
test
sampl
score
studi
immunoassay
test
studi
e
f
f
blind
virolog
test
result
biomark
measur
sampl
score
sampl
collect
patient
health
care
provid
flock
swab
place
univers
viral
transport
medium
becton
dickinson
nucleic
acid
isol
ml
transport
medium
use
nuclisen
boom
method
easi
mag
instrument
biomerieux
dfa
test
perform
use
commerci
reagent
light
diagnost
simulfluor
respiratori
screen
reagent
millipor
corpor
pcr
direct
fluoresc
antigen
test
panel
respiratori
virus
tabl
perform
describ
previous
coronaviru
multiplex
pcr
assay
adopt
sultani
et
al
covsar
confirm
posit
sampl
perform
use
singleplex
pcr
test
perform
use
previous
report
assay
sourc
rna
studi
rna
cell
pellet
studi
nucleic
acid
clinic
virolog
test
follow
genom
dna
digest
rt
iscript
gdna
clear
biorad
laboratori
rna
isol
cell
pellet
use
rneasi
kit
qiagen
reversetranscrib
rna
use
iscript
cdna
synthesi
kit
biorad
laboratori
qpcr
perform
use
itaq
univers
sybr
green
biorad
laboratori
primer
frozen
viral
transport
medium
thaw
ice
centrifug
remov
cell
debri
chemokin
level
measur
use
bioplex
luminex
instrument
milliplex
map
human
cytokin
panel
iii
bioplex
pro
human
chemokin
panel
follow
manufactur
instruct
biorad
laboratori
millipor
corpor
measur
undilut
dilut
sampl
data
analysi
employ
sasstat
statist
analysi
softwar
ibm
spss
statist
analysi
softwar
respiratori
epitheli
cell
mount
vigor
antivir
defens
respons
upon
viral
recognit
cellintrins
innat
immun
system
rapid
induct
antivir
gene
identifi
robust
biomark
antivir
respons
human
nasal
epitheli
cell
hnec
stimul
hnec
vitro
small
molecul
ligand
rigi
cytoplasm
receptor
viral
rna
although
treatment
stimul
rigi
mimick
rna
viru
infect
analog
sensor
dna
virus
trigger
mani
downstream
signal
consist
previou
studi
airway
epitheli
cell
respond
viral
infect
transcript
chang
domin
interferonstimul
gene
isg
figur
supplementari
tabl
includ
mrna
associ
respiratori
viru
infect
sampl
type
patient
popul
includ
ifit
gene
oa
gene
figur
highlight
highli
induc
transcript
evalu
potenti
biomark
studi
includ
multipl
chemokin
small
secret
protein
function
chemoattract
recruit
cell
immun
system
infect
tissu
transcript
encod
secret
protein
particular
interest
could
potenti
serv
biomark
viral
infect
rna
protein
level
therefor
could
use
develop
pcrbase
immunoassaybas
diagnost
test
next
investig
whether
transcript
signatur
base
identifi
mrna
could
predict
viral
infect
nasopharyng
swab
perform
rtqpcr
biomark
rna
isol
np
swab
sent
ynhh
lab
respiratori
viru
test
chart
review
reveal
patient
older
adult
multipl
comorbid
present
respiratori
symptom
andor
fever
andor
alter
mental
statu
top
comorbid
cardiovascular
diseas
malign
asthmacopd
see
supplementari
figur
measur
level
mrna
identifi
rnaseq
experi
encod
intracellular
protein
oasl
encod
chemokin
level
biomark
correl
highli
viru
detect
figur
supplementari
figur
mrna
signatur
test
score
mrna
level
cutoff
determin
mrna
level
detect
stimul
hnec
least
mrna
cutoff
given
sampl
sampl
score
posit
viral
infect
sampl
score
posit
host
respons
test
also
test
posit
known
respiratori
virus
ynhh
panel
tabl
figur
ynhh
viru
panel
includ
coronavirus
cov
therefor
test
rna
patient
sampl
use
previous
describ
multiplex
assay
cov
genotyp
specimen
posit
coronaviru
strikingli
biomarkerposit
viru
panelneg
sampl
posit
indic
asterisk
next
bar
viru
panel
figur
cov
detect
codetect
sampl
posit
virus
shown
figur
overal
diagnost
accuraci
mrna
biomark
test
confid
interv
ci
posit
predict
valu
ci
two
sampl
repres
fals
neg
viru
detect
absenc
isg
signatur
includ
rhinoviru
rv
human
metapneumoviru
hmpv
sampl
sampl
patient
asthma
copd
viru
posit
biomark
test
posit
biomark
test
neg
hmpv
sampl
virusneg
sampl
asthma
copd
patient
biomark
test
neg
seven
distinct
virus
detect
sampl
convent
mrna
signatur
test
figur
mimic
viral
infect
primari
human
nasal
epitheli
cell
hnec
transfect
hour
incub
addit
hour
follow
rna
isol
transcript
analysi
rnaseq
dot
repres
transcript
significantli
differ
control
versu
stimul
hnec
adjust
pvalu
log
foldchang
label
highlight
transcript
examin
studi
potenti
nasopharyng
biomark
viral
respiratori
infect
extens
list
differenti
express
transcript
found
supplementari
tabl
indic
great
potenti
singl
hostbas
test
captur
infect
divers
virus
base
chart
review
patient
find
indic
nonvir
infect
see
supplementari
tabl
seven
viru
neg
patient
also
neg
host
mrna
signatur
describ
figur
addit
patient
radiolog
evid
bacteri
infect
sputum
cultur
posit
pseudomona
patient
also
test
posit
coronaviru
host
signatur
viral
infect
describ
figur
although
studi
design
assess
nonvir
infect
data
suggest
host
respons
signatur
figur
specif
viral
infect
trigger
inhibit
infect
type
indic
figur
supplementari
tabl
highli
induc
mrna
trigger
rigi
ligand
nasal
cell
vitro
encod
chemokin
identifi
chemokin
might
serv
robust
biomark
viral
infect
protein
level
measur
level
chemokin
identifi
rnaseq
experi
use
immunoassay
viral
transport
medium
chemokin
test
level
correl
presenc
viru
show
robust
correl
figur
evalu
use
andor
protein
predict
respiratori
viru
infect
measur
level
protein
viral
transport
medium
second
set
store
sampl
decemb
patient
primarili
older
adult
patient
age
also
includ
young
children
patient
vs
studi
supplementari
figur
concentr
correl
highli
viral
infect
figur
sampl
initi
test
panel
cov
studi
result
compar
biomark
level
sever
virusneg
sampl
high
level
expand
test
panel
test
parainfluenza
viru
type
three
sampl
test
posit
includ
sampl
high
level
viru
detect
figur
show
expand
view
sampl
highest
level
detect
tabl
cov
coronaviru
cov
detect
npv
neg
predict
valu
ppv
posit
predict
valu
virus
origin
test
panel
tabl
figur
c
preval
individu
virus
differ
significantli
studi
respiratori
syncyti
viru
preval
studi
rv
preval
studi
figur
find
reveal
concentr
predict
infect
divers
virus
figur
show
protein
concentr
sampl
studi
plu
studi
sort
highest
lowest
concentr
bar
viru
column
indic
viru
detect
shown
high
level
correl
strongli
viru
detect
low
level
correl
absenc
viru
intermedi
level
indetermin
base
pattern
possibl
envis
develop
ruleinruleout
test
use
high
cutoff
sampl
predict
viru
posit
sampl
predict
viru
neg
dash
grey
line
figur
repres
cutoff
pgml
rulein
sampl
set
would
posit
predict
valu
ppv
cutoff
pgml
ppv
dot
black
line
indic
low
cutoff
pgml
test
neg
predict
valu
absenc
viru
infect
use
cutoff
pgml
pgml
sampl
fall
indetermin
zone
consist
observ
studi
figur
observ
high
degre
correl
protein
concentr
supplementari
figur
measur
could
use
rule
rule
viru
infect
sum
result
demonstr
immunoassaybas
test
measur
singl
host
protein
could
high
diagnost
util
manag
patient
suspect
respiratori
infect
studi
test
whether
mrna
protein
associ
np
swab
could
use
predict
detect
respiratori
viru
sampl
sent
hospit
laboratori
convent
virolog
test
chose
possibl
biomark
base
transcript
strongli
induc
viruslik
stimulu
primari
nasal
epitheli
cell
vitro
mrna
select
show
predict
valu
viral
infect
np
swab
surprisingli
also
abl
identifi
highperform
biomark
detect
protein
level
test
chemokin
indic
vitro
experi
mrna
protein
biomark
identifi
molecul
known
associ
antivir
interferon
respons
key
host
defens
respons
rna
dna
virus
viral
recognit
lead
interferon
secret
induct
approxim
differ
antivir
effector
result
unexpect
interferonstimul
gene
divers
regulatori
mechan
differenti
express
differ
host
tissu
differenti
antagon
differ
virus
therefor
identifi
one
perform
best
panvir
infect
biomark
upper
respiratori
tract
requir
empir
test
interestingli
although
mani
differ
chemokin
induc
rigi
stimul
vitro
famili
chemokin
correl
highli
viral
infect
np
swab
sampl
ligand
ligand
mediat
chemotaxi
cell
site
viral
infect
consist
correl
chemokin
presenc
divers
respiratori
virus
np
swab
suggest
particularli
robust
conserv
role
chemokin
local
antivir
defens
upper
respiratori
tract
abl
identifi
accur
mrna
proteinbas
test
defin
mrna
signatur
high
diagnost
accuraci
combin
inform
biomark
figur
accuraci
ci
sensit
specif
test
compar
favor
recent
report
mrnabas
index
correl
viperin
mrna
level
viral
infect
technolog
support
practic
test
base
measur
host
transcript
activ
develop
importantli
find
show
np
swabassoci
protein
concentr
also
serv
biomark
viral
infect
immunoassay
alreadi
wide
use
diagnost
test
find
open
new
possibl
develop
practic
test
divers
patient
care
set
includ
pointofcar
notabl
observ
discord
sampl
biomarkerneg
virusposit
sampl
could
repres
infect
current
part
activ
diseas
process
recent
studi
show
host
antivir
respons
detect
respiratori
tract
asymptomat
virusinfect
subject
magnitud
transcript
respons
possibl
presenc
respons
protein
level
greater
symptomat
asymptomat
subject
consist
analysi
rhinovirusposit
sampl
studi
show
clear
correl
low
low
viral
load
supplementari
figur
biomarkerposit
virusneg
sampl
could
repres
infect
untest
virus
appli
technolog
deep
sequenc
viral
identif
could
provid
greater
estim
biomark
accuraci
futur
studi
also
import
rule
nonvir
biolog
process
lead
biomark
elev
exampl
elev
chemokin
report
chronic
respiratori
diseas
encouragingli
initi
result
indic
specif
biomark
test
viru
infect
popul
studi
patient
copd
asthma
patient
viru
neg
patient
also
test
viru
neg
host
mrna
biomark
signatur
figur
futur
studi
import
explor
perform
biomark
differ
patient
popul
clinic
set
studi
focus
patient
undergo
respiratori
viru
test
health
care
system
larg
older
adult
young
children
patient
popul
biomarkerbas
test
could
provid
simpl
costeffect
method
rule
inrul
viral
infect
caus
symptom
andor
determin
patient
requir
addit
virolog
test
biomark
perform
well
outpati
acut
upper
respiratori
infect
possibl
imagin
transform
new
test
aid
rapid
diagnosi
common
ill
promot
antimicrobi
stewardship
exampl
panvir
biomark
could
potenti
pair
analog
biomark
bacteri
respiratori
infect
distinguish
among
viral
infect
bacteri
infect
viralbacteri
coinfect
studi
observ
nonvir
infect
trigger
viru
host
respons
signatur
supplementari
tabl
indic
potenti
feasibl
approach
addit
biomarkerbas
test
offer
advantag
tradit
virolog
panel
includ
identifi
patient
infect
unexpect
virus
exampl
studi
biomark
identifi
sampl
posit
virus
origin
test
panel
see
figur
bar
indic
asterisk
viru
column
illustr
biomark
test
could
employ
surveil
unexpect
virus
includ
emerg
respiratori
virus
also
biomarkerbas
test
offer
promis
distinguish
incident
viru
detect
activ
viral
infect
issu
come
focu
incident
respiratori
viru
detect
increasingli
recogn
highli
preval
asymptomat
subject
sum
result
show
biomark
antivir
respons
robustli
detect
use
nasopharyng
swab
includ
protein
biomark
detect
immunoassay
even
singl
biomark
detect
use
minim
invas
sampl
type
offer
high
diagnost
accuraci
result
compel
studi
use
nasopharyng
biomark
improv
understand
hostviru
interact
improv
diagnosi
manag
patient
respiratori
ill
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
